SK Inc., the Second Largest Conglomerate in South Korea, has invested $350 million in the Center for Breakthrough Medicines

The Center for Breakthrough Medicines (CBM) announced today that it has received $350 million in equity financing from SK Inc. (KRX: 034730) (SK). CBM is partnering with SK to create the world’s …